Effect of alpha-adrenergic and serotonergic blockers on the acute irritative response in the rabbit eye.
The effect of alpha-adrenergic and serotonergic (5-HT) blockers on the acute irritative response in the rabbit eye elicited by topical, neutral formaldehyde (1%), was studied. In the control animals, the peak rise in the intraocular pressure (delta IOP) after irritation was 29.5 +/- 5.7 mm Hg, and the perfusion pressure of the eye at 1 min after irritation was 50.1 +/- 2.8 mm Hg. The peak rise in the IOP was inhibited by phentolamine (alpha- and 5-HT-antagonist, delta IOP = 6.6 +/- 2.1 mm Hg, P less than 0.01), methysergide (5-HT-antagonist, delta IOP = 10.6 +/- 4.4 mm Hg, P less than 0.05), and prazosin (alpha 1-antagonist, delta IOP = 12.8 +/- 3.7 mm Hg, P less than 0.05). Perfusion pressures of the eyes were decreased after pretreatment with phentolamine or prazosin, and were 35.2 +/- 4.8 mm Hg (P less than 0.05) and 25.7 +/- 3.7 mm Hg (P less than 0.01), respectively. Perfusion pressure in the methysergide group remained unchanged (75.4 +/- 14.2 mm Hg). Yohimbine (alpha 2-antagonist) and ketanserin (5-HT2-antagonist) did not inhibit the IOP response. None of the antagonists could inhibit the miosis or disruption of the blood-aqueous barrier induced by topical neutral formaldehyde. In the contralateral eyes, the changes in the IOP, in the integrity of the blood-aqueous barrier, and also in the pupil size, were enhanced by ketanserin. The present study demonstrates the inhibitory actions of methysergide, phentolamine, and prazosin on the neurally mediated, acute irritative response in the rabbit eye. Methysergide seems to inhibit the response, probably acting via the 5-HT1-receptors. A part of the effect of phentolamine might be explained by an inhibitory action via 5-HT1-receptors. The effect of phentolamine and prazosin on the alpha 1-receptors seems to create an inhibitory action on the irritative response by lowering the perfusion pressure of the eye.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000818:Animals; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D005128:Eye Diseases / Q000139:chemically induced / Q000517:prevention & control*; D005136:Eye Proteins / Q000378:metabolism; D005260:Female; D005557:Formaldehyde; D007429:Intraocular Pressure / Q000187:drug effects; D007650:Ketanserin / Q000627:therapeutic use; D008297:Male; D008784:Methysergide / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011680:Pupil / Q000187:drug effects; D011817:Rabbits; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D015016:Yohimbine / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D005136:Eye Proteins; D012702:Serotonin Antagonists; D005557:Formaldehyde; D015016:Yohimbine; D007650:Ketanserin; D011224:Prazosin; D008784:Methysergide; D010646:Phentolamine